Erectile Dysfunction

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Key Research Papers
Connections
Featured Videos

1. Overview

Erectile Dysfunction (ED) is defined as the persistent or recurrent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. The condition must be present for at least six months to distinguish it from transient situational difficulty. Erectile dysfunction is among the most prevalent male sexual disorders worldwide and has profound implications for self-esteem, relationship quality, and overall psychological well-being.

Beyond its direct impact on sexual health, erectile dysfunction carries important clinical significance as a harbinger of systemic cardiovascular disease. Because the penile arteries (cavernosal diameter 1–2 mm) are smaller than coronary arteries (3–4 mm) and affected by endothelial dysfunction at earlier stages, erectile dysfunction often precedes symptomatic coronary artery disease by 2–5 years, providing a critical window for cardiovascular risk reduction.

2. Epidemiology

The Massachusetts Male Aging Study (MMAS) — a landmark community-based cohort — reported that approximately 52% of men aged 40–70 years experience some degree of erectile dysfunction, with complete erectile dysfunction in 10%, moderate in 25%, and minimal in 17%. Global prevalence estimates suggest that over 300 million men worldwide will be affected by 2025, reflecting aging populations and rising rates of metabolic risk factors.

Prevalence increases sharply with age: approximately 5–10% in men under 40, 20–30% in men aged 40–59, 40–60% in men aged 60–69, and over 70% in men aged 70 and above. Importantly, younger men (under 40) appear to represent a growing proportion of clinical presentations, with psychogenic and lifestyle factors predominating. Men with diabetes, cardiovascular disease, hypogonadism, or depression carry severalfold higher prevalence than age-matched controls.

3. Pathophysiology

Penile erection is a neurovascular event modulated by psychological, hormonal, and local vascular factors.

Normal Erectile Physiology

Sexual stimulation activates parasympathetic (S2–S4) and non-adrenergic non-cholinergic (NANC) nerve fibers, releasing nitric oxide (NO) from cavernous nerve terminals and vascular endothelium. NO activates soluble guanylyl cyclase, increasing cyclic guanosine monophosphate (cGMP), which activates protein kinase G. PKG phosphorylates myosin light chain phosphatase and potassium channels, reducing intracellular calcium and causing smooth muscle relaxation in the corpora cavernosa and helicine arteries. Increased arterial inflow, engorgement of the sinusoidal spaces, and compression of emissary veins against the tunica albuginea produce the veno-occlusive mechanism responsible for sustained erection.

Detumescence is mediated by sympathetic activation (norepinephrine-mediated smooth muscle contraction) and phosphodiesterase type 5 (PDE5), which hydrolyzes cGMP, restoring basal vascular tone.

Mechanisms of Erectile Dysfunction

Vascular (endothelial) dysfunction: The most common mechanism in organic erectile dysfunction. Reduced endothelial NO bioavailability — due to oxidative stress, dyslipidemia, hyperglycemia, or hypertension — impairs smooth muscle relaxation. Atherosclerotic plaques in the pudendal, iliac, or cavernosal arteries reduce arterial inflow.
Venous leak (corporal veno-occlusive dysfunction): Structural changes in the tunica albuginea (fibrosis, reduced elastin) or cavernosal smooth muscle (fibrosis from ischemia, Peyronie's disease) prevent adequate veno-occlusion.
Neurogenic mechanisms: Damage to cavernous nerve fibers (radical prostatectomy, pelvic radiation, diabetes-associated autonomic neuropathy, multiple sclerosis, spinal cord injury) abolishes NO release at the cavernosal nerve terminal.
Hormonal mechanisms: Testosterone modulates expression of NOS isoforms, PDE5, and maintains cavernosal smooth muscle architecture. Hypogonadism reduces NO synthesis and increases corporal fibrosis. Hyperprolactinemia suppresses gonadotropin secretion and testosterone production.
Psychogenic mechanisms: Anxiety, depression, relationship conflict, and performance anxiety activate the sympathetic nervous system, increasing adrenergic tone and inhibiting parasympathetic pro-erectile signaling. Central serotonergic and dopaminergic pathway dysregulation is also implicated.

4. Etiology and Risk Factors

Cardiovascular and Metabolic Risk Factors

Atherosclerosis and hypertension: Endothelial dysfunction is the shared pathophysiologic link between erectile dysfunction and cardiovascular disease.
Diabetes mellitus: Two to three times greater erectile dysfunction prevalence; combined endothelial, autonomic, and hormonal mechanisms; earlier onset by 10–15 years.
Dyslipidemia: High low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) reduce endothelial NO production via oxidized low-density lipoprotein-mediated eNOS inhibition.
Obesity: Associated with hypogonadism (aromatization of androgens), insulin resistance, sleep apnea, and systemic endothelial dysfunction.
Metabolic syndrome: Encompasses and amplifies multiple individual risk factors.

Hormonal Causes

Hypogonadism: Primary (testicular) or secondary (pituitary/hypothalamic); testosterone deficiency impairs NO-mediated erectile mechanisms.
Hyperprolactinemia: Pituitary adenoma (macro or micro) suppresses luteinizing hormone (LH)/follicle-stimulating hormone (FSH) and testosterone.
Thyroid dysfunction: Both hypothyroidism and hyperthyroidism are associated with erectile dysfunction through hormonal and vascular mechanisms.

Neurological Causes

Radical prostatectomy (cavernous nerve injury): erectile dysfunction rates of 40–80% depending on surgical technique and nerve-sparing status.
Pelvic radiation therapy
Spinal cord injury (erections preserved with S2–S4 intact reflexogenic arc)
Diabetic autonomic neuropathy
Multiple sclerosis, Parkinson's disease, stroke

Medications

Antihypertensives: beta-blockers (most), thiazide diuretics; calcium channel blockers and angiotensin-converting enzyme inhibitors (ACE inhibitors) are relatively sparing
Antidepressants: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (reduced libido and orgasmic dysfunction predominate; direct erectile dysfunction less common)
Antipsychotics: dopamine receptor blockade and hyperprolactinemia
Antiandrogens (finasteride, dutasteride, spironolactone, GnRH agonists)
Recreational drugs: alcohol, cocaine, heroin, cannabis (chronic use)

Psychogenic and Relationship Factors

Performance anxiety, generalized anxiety disorder, depression
Relationship conflict, partner sexual dysfunction
Post-traumatic stress disorder (PTSD)
Pornography-associated erectile dysfunction in younger men

Structural/Local Causes

Peyronie's disease: fibrous plaque formation in the tunica albuginea causing penile curvature and pain
Priapism-associated fibrosis
Penile trauma

5. Clinical Presentation

The diagnosis of erectile dysfunction is primarily established by history. The chief complaint is the inability to achieve or maintain erections adequate for sexual intercourse. The history covers:

Onset (gradual versus sudden) and duration
Presence or absence of morning/nocturnal erections (preserved spontaneous erections favor psychogenic etiology)
Erection firmness, penetration ability, and maintenance during intercourse
Libido (reduced libido suggests hormonal etiology)
Ejaculatory and orgasmic function
Relationship status and partner factors

International Index of Erectile Function (IIEF)

The IIEF-5 (Sexual Health Inventory for Men, SHIM) is the most widely used validated instrument for erectile dysfunction assessment. Five questions scored 1–5 yield a maximum of 25 points. Severity classification:

Severe erectile dysfunction: 5–7
Moderate erectile dysfunction: 8–11
Mild-to-moderate erectile dysfunction: 12–16
Mild erectile dysfunction: 17–21
No erectile dysfunction: 22–25

The full 15-item IIEF assesses five domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction, providing a comprehensive sexual health profile.

6. Diagnosis

Laboratory Evaluation

Recommended initial laboratory assessment includes:

Fasting glucose and hemoglobin A1c (HbA1c): Screen for diabetes mellitus
Fasting lipid panel: Cardiovascular risk stratification
Total testosterone (morning, 8–10 AM): Assesses hypogonadism; if low, confirm with repeat measurement and add free testosterone, luteinizing hormone, follicle-stimulating hormone, prolactin, and SHBG
Prostate-specific antigen (PSA): In age-appropriate men being considered for testosterone therapy
Thyroid-stimulating hormone (TSH): If thyroid dysfunction suspected
Complete blood count (CBC), renal function, liver function: In selected patients with systemic disease history

Cardiovascular Risk Assessment

The Princeton Consensus guidelines recommend that all men presenting with erectile dysfunction be assessed for cardiovascular risk. Men with erectile dysfunction and intermediate cardiovascular risk (e.g., multiple risk factors but asymptomatic) may warrant exercise stress testing or coronary calcium scoring before initiating PDE5 inhibitor therapy or sexual activity.

Nocturnal Penile Tumescence and Rigidity (NPTR)

A bedside rigidity monitor measures penile tumescence and rigidity at the tip and base during sleep. Under the European Association of Urology (EAU) guidelines, the test is run on at least two separate nights, and a working erectile mechanism is shown by an erectile event of at least 60% rigidity at the tip of the penis lasting 10 minutes or more; men with psychogenic erectile dysfunction usually have normal findings, which is how the test helps tell psychogenic from organic erectile dysfunction. Primarily indicated in medicolegal cases or when the distinction significantly alters management.

Penile Duplex Doppler Ultrasound

Gold standard for assessing penile arterial inflow and venous leak. Performed after intracavernosal injection of a vasoactive agent (prostaglandin E1 10–20 mcg). Normal, per the EAU guidelines: peak systolic velocity (PSV) above 30 cm/s, end diastolic velocity (EDV) below 3 cm/s, resistive index (RI) above 0.8. Arterial insufficiency: PSV below 25 cm/s. Veno-occlusive dysfunction: EDV above 5 cm/s with RI below 0.75.

Arteriography and Dynamic Infusion Cavernosometry

Reserved for surgical candidates (young men with post-traumatic arterial insufficiency or veno-occlusive dysfunction) in whom revascularization or venous ligation is being considered.

7. Treatment

Lifestyle Modification and Risk Factor Management

As the most evidence-based intervention for erectile dysfunction related to cardiovascular risk factors:

Exercise: In a 2-year trial in 110 obese men (Esposito et al., JAMA 2004), the men given detailed advice on losing 10% or more of their body weight by eating fewer calories and being more active (their weekly activity rose from about 48 to 195 minutes) raised their average erectile function (IIEF) score from 13.9 to 17, and about one third reached a score of 22 or higher, the normal range (17 men, against 3 in the control group). Pelvic floor exercises (Kegel) improve venous occlusion and erection quality.
Weight loss: A 10% weight reduction in obese men restores normal erectile function in approximately one-third of patients.
Smoking cessation, alcohol reduction
Optimization of systemic diseases: Glycemic control, blood pressure, and lipid management are first-line disease-modifying interventions.

Phosphodiesterase Type 5 Inhibitors (PDE5i)

PDE5 inhibitors are the first-line pharmacological treatment for erectile dysfunction of all etiologies except when contraindicated. They enhance endogenous NO/cGMP signaling by preventing cGMP hydrolysis, requiring sexual stimulation for effect.

Sildenafil: 25–100 mg on demand, 30–60 minutes before sexual activity; duration 4–6 hours; high-fat meals reduce absorption.
Tadalafil: 10–20 mg on demand (half-life 17–21 hours; window 36 hours) or 2.5–5 mg once daily (continuous dosing restores natural erectile spontaneity); also approved for BPH-LUTS.
Vardenafil: 5–20 mg on demand; pharmacokinetics similar to sildenafil.
Avanafil: 50–200 mg; fastest onset (15–30 minutes); fewer visual side effects due to minimal PDE6 inhibition.

Contraindications: the drug labels contraindicate nitric oxide donors such as organic nitrates or nitrites in any form, taken regularly or only now and then, and nicorandil (risk of severe hypotension), as well as guanylate cyclase stimulators such as riociguat. The labels count any waiting time from the last PDE5-inhibitor dose: when a nitrate is needed in a life-threatening situation, the tadalafil label says at least 48 hours should pass after the last tadalafil dose and the avanafil label says 12 hours, while the sildenafil label says it is unknown when nitrates can be safely given. With alpha-blockers the labels advise caution, because using the two together may lead to low blood pressure (hypotension). Common side effects: headache, flushing, nasal congestion, dyspepsia, myalgia, and transient visual color changes (sildenafil — PDE6 cross-reactivity).

The labels also carry three warnings: an erection lasting more than 4 hours is an emergency, because untreated priapism can permanently damage the penis; a sudden loss of vision in one or both eyes, which can be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), and a sudden decrease or loss of hearing are reasons the labels give to stop the drug and get prompt medical care.

Response rates: approximately 70% of unselected erectile dysfunction patients; reduced in severe diabetes (50–60%), post-radical prostatectomy without nerve sparing (15–25%), and severe vascular disease.

Testosterone Replacement Therapy (TRT)

Indicated for men with confirmed hypogonadism (morning total testosterone persistently below 300 ng/dL with symptoms). TRT alone may restore erectile function in hypogonadal men; TRT combined with PDE5 inhibitors is synergistic. Available formulations include transdermal gels, intramuscular injections (testosterone cypionate/enanthate every 1–2 weeks or undecanoate every 10 weeks), subcutaneous pellets, and buccal systems.

Vacuum Erection Devices (VED)

Non-pharmacological, mechanical option creating negative pressure around the penis to draw blood into the corpora cavernosa; a constriction ring maintains erection. Particularly useful post-prostatectomy or for penile rehabilitation. Patient satisfaction approximately 70–90% with proper instruction; pivotal concerns include pivoting sensation, ejaculatory restriction, and ecchymosis.

Intracavernosal Injections (ICI)

An injection treatment with response rates of 85–90%. The 2018 American Urological Association (AUA) guideline no longer ranks treatments as first-, second- or third-line: it presents every treatment that is not contraindicated as a potential first-line option. Alprostadil (PGE1) 5–40 mcg, alone or in combination (Trimix: alprostadil + phentolamine + papaverine). Self-administered 10–20 minutes before intercourse. Side effects include penile pain (alprostadil), priapism (less than 1%), and corporal fibrosis with repeated use. Priapism (erection exceeding 4 hours) requires emergency aspiration and intracavernosal phenylephrine injection.

Intraurethral Alprostadil

Medicated urethral suppository delivering alprostadil (125–1000 mcg); absorbed through the urethral mucosa into the corpora. Less effective than ICI (response rate 40–50%) but less invasive. Urethral burning is common.

Penile Prosthesis (Implant)

A definitive surgical treatment offering the highest satisfaction rates (patient and partner satisfaction approximately 90–95%); the 2018 AUA guideline presents it, like the other treatments that are not contraindicated, as a potential first-line option. Indicated for erectile dysfunction refractory to or contraindicated for medical therapy.

Inflatable penile prosthesis (IPP, 3-piece): Two corporal cylinders connected to a scrotal pump and abdominal reservoir. Three-piece inflatable implants are U.S. Food and Drug Administration-approved devices. Provides on-demand erection with natural flaccidity when deflated.
Malleable (semi-rigid) prosthesis: Bendable rods implanted bilaterally; simpler device; always semi-erect but can be positioned downward.

Infection is the most feared complication (1–3%); antibiotic- or hydrophilic-coated implants reduce infection rates to 0.5–1%. Mechanical revision rate approximately 5% at 5 years.

Psychological and Psychosexual Therapy

Cognitive behavioral sex therapy, mindfulness-based interventions, and couple therapy are indicated for psychogenic erectile dysfunction or when psychological factors complicate organic erectile dysfunction. Combination of PDE5i and psychotherapy is superior to either alone in men with significant performance anxiety.

Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)

Acoustic shockwave energy stimulates neovascularization, endothelial cell proliferation, and cavernosal nerve regeneration, potentially modifying the underlying vascular disease rather than merely treating symptoms. The EAU guidelines note that several single-arm trials have shown a benefit on men's reported erectile function, with wide differences between shockwave devices, settings and treatment protocols. In the sham-controlled trial of linear low-intensity shockwave therapy in 126 men cited on this page (Fojecki 2017), success rates were 37.9% with shockwave therapy and 38.3% with sham treatment, and the authors found no clinically relevant effect. Optimal protocol and patient selection (best results in mild-to-moderate vasculogenic erectile dysfunction) remain under investigation.

8. Complications

Cardiovascular events: erectile dysfunction is an independent predictor of major adverse cardiovascular events (MACE), myocardial infarction, and all-cause mortality, with hazard ratios of 1.3–2.0 after confounders are controlled.
Psychological impact: Untreated erectile dysfunction causes significant depression, anxiety, shame, and diminished masculine self-concept. Relationship breakdown and sexual avoidance are common.
Priapism from treatment: Intracavernosal therapy-induced ischemic priapism causes permanent corporal fibrosis and worsened erectile dysfunction if not treated within 4–6 hours.
Peyronie's disease: erectile dysfunction and Peyronie's coexist in 30–60% of men; corporal fibrosis from both conditions can become self-reinforcing.
Partner sexual dysfunction: Female partners of men with erectile dysfunction have higher rates of sexual dysfunction, depression, and relationship dissatisfaction.

9. Prognosis

The prognosis for erectile dysfunction depends heavily on etiology, severity, and the presence and reversibility of underlying risk factors. Men with psychogenic erectile dysfunction in the absence of organic disease have excellent prognosis with psychotherapy and PDE5 inhibitors. Men who successfully modify cardiovascular risk factors (weight loss, exercise, smoking cessation, optimized glycemic control) experience clinically meaningful spontaneous improvement in erectile function in approximately 30–50% of cases.

Post-radical prostatectomy erectile dysfunction follows a predictable nerve-regeneration timeline; return of function typically occurs over 6–24 months and is strongly predicted by nerve-sparing technique, surgeon volume, and patient age and baseline erectile function. PDE5 inhibitor penile rehabilitation (daily low-dose tadalafil) aims to speed recovery by keeping the cavernosal smooth muscle oxygenated during the nerve recovery period; a 2013 review (Fode et al.) found that animal studies support it but results from human studies are contradictory, and the largest study to date found no long-term effect of daily or on-demand PDE5 inhibitors after radical prostatectomy compared with placebo.

10. Prevention

Cardiovascular health maintenance: Aggressive management of hypertension, diabetes, dyslipidemia, and obesity.
Regular aerobic and pelvic floor exercise
Smoking cessation
Moderate alcohol intake
Nerve-sparing radical prostatectomy and prostate-sparing radiation techniques
PDE5 inhibitor penile rehabilitation after radical prostatectomy or pelvic radiation (supported by animal studies; human results are contradictory, per the 2013 review by Fode et al.)
Medication review: Substituting erectile dysfunction-causing antihypertensives (beta-blockers, thiazides) with alternatives (angiotensin receptor blockers (ARBs), nebivolol) when clinically appropriate
Mental health treatment: Early intervention for depression and anxiety reduces risk of secondary psychogenic erectile dysfunction

11. Recent Research and Advances

Stem cell therapy: Intracavernosal injection of adipose-derived stem cells (ADSCs), bone marrow-derived mesenchymal stem cells, and platelet-rich plasma (PRP) is under clinical investigation for neurogenic and vasculogenic erectile dysfunction. Phase I/II trials show safety and preliminary efficacy signals for cavernous nerve injury models.

Gene therapy: Naked-DNA (plasmid) transfer of hSlo (the human BKCa, or Maxi-K, potassium channel gene) improved erectile function and sexual behaviour in eight cynomolgus monkeys with atherosclerosis (Christ et al., 2009). In the first human Phase I trial (Melman et al., 2006), 11 men received a single injection of the plasmid and were followed for 24 weeks: there were no serious adverse events, the men given the two highest doses had apparent improvements in erectile function scores, and the authors stated that efficacy conclusions cannot be drawn from a phase I trial with no control group. VEGF gene therapy targeting cavernosal angiogenesis is in early trials.

Melanocortin agonists: Bremelanotide (PT-141), a melanocortin receptor agonist acting centrally, is approved for hypoactive sexual desire disorder in women and shows promise for psychogenic and mixed erectile dysfunction through non-NO-dependent central pro-erectile mechanisms.

Topical alprostadil: Cream formulation applied to the urethral meatus; approved in Europe and Canada; avoids injection while providing local vasodilation.

Pulsed electromagnetic field therapy (PEMF) and low-intensity laser therapy: Emerging non-invasive modalities targeting cavernosal endothelial regeneration with phase II trial data suggesting additive benefit to PDE5 inhibitors.

Gut microbiome and erectile dysfunction: Reduced bacterial diversity and altered short-chain fatty acid production are linked to endothelial dysfunction and testosterone metabolism, opening microbiome-targeted interventions as a future direction.

Key Research Papers

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61. — doi:10.1016/S0022-5347(17)34871-1
Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633–641. — doi:10.1016/j.juro.2018.05.004
Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol. 2006;50(4):721–731. — doi:10.1016/j.eururo.2006.07.015
Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978–2984. — doi:10.1001/jama.291.24.2978
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–830. — doi:10.1016/S0090-4295(97)00238-0
Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–284. — doi:10.1111/j.1743-6109.2012.02783.x
Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–814. — doi:10.1016/j.eururo.2010.02.020
Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int. 2004;93(9):1276–1281. — doi:10.1111/j.1464-410X.2004.04819.x
Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230–239. — doi:10.1097/01.ju.0000164463.19239.19
Fode M, Ohl DA, Ralph D, Sonksen J. Penile rehabilitation after radical prostatectomy: what the evidence really says. BJU Int. 2013;112(7):998–1008. — doi:10.1111/bju.12228
Fojecki GL, Tiessen S, Osther PJ. Effect of low-energy linear shockwave therapy on erectile dysfunction: a double-blinded, sham-controlled, randomized clinical trial. J Sex Med. 2017;14(1):106–112. — doi:10.1016/j.jsxm.2016.11.307
Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003. — doi:10.1038/nrdp.2016.3
Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(9):2445–2454. — doi:10.1111/j.1743-6109.2009.01354.x
Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–165. — doi:10.1016/S0140-6736(12)60520-0
Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the erection hardness score. J Sex Med. 2007;4(6):1626–1634. — doi:10.1111/j.1743-6109.2007.00600.x

PubMed Topic Searches

Back to Table of Contents

Connections

Urology
Hypertension
Arginine
Benign Prostatic Hyperplasia
Low Testosterone / TRT
Zinc
Ginseng
Vitamin D3
Testosterone Test
Diabetes
Depression
Anxiety
Obesity
Cardiovascular Disease
Metabolic Syndrome
Atherosclerosis
Fasting
Peripheral Artery Disease
Prostate Conditions
Prostate Cancer
Herbs covered on this site that discuss this condition: Saw Palmetto (Serenoa repens) · Damiana · Muira Puama · Black Ginger (Kaempferia parviflora) · Tribulus terrestris · Marsh Barbel (Hygrophila auriculata)
Discussed in depth on these pages: Sexual Function and the Icariin PDE5 Question
Yohimbe
Cardiology
Herbs

↑ Back to Table of Contents